-
1 week ago | 
venturecapital.createsend1.com | Brian Gormley
Good day. Startup Creyon Bio has formed a collaboration with drugmaker Eli Lilly that could be worth more than $1 billion, the companies say.
Creyon, whose investors include DCVC Bio and Lux Capital, has technology capable of designing oligonucleotides, or short nucleic-acid sequences, that could be used to treat a range of diseases.
-
1 week ago | 
createsend.com | Brian Gormley
Good day. Startup Creyon Bio has formed a collaboration with drugmaker Eli Lilly that could be worth more than $1 billion, the companies say.
Creyon, whose investors include DCVC Bio and Lux Capital, has technology capable of designing oligonucleotides, or short nucleic-acid sequences, that could be used to treat a range of diseases.
-
1 week ago | 
venturecapital.cmail19.com | Brian Gormley
Good day. Startup Creyon Bio has formed a collaboration with drugmaker Eli Lilly that could be worth more than $1 billion, the companies say.
Creyon, whose investors include DCVC Bio and Lux Capital, has technology capable of designing oligonucleotides, or short nucleic-acid sequences, that could be used to treat a range of diseases.
-
1 week ago | 
wsj.com | Brian Gormley
Dr. Kate Knobil joins the biotech as it looks to combat a viral infection that can be dangerous to patients with the lung disease COPDMay 1, 2025 6:00 am ET|WSJ ProAltesa BioSciences has hired a top pharmaceutical executive to help develop a drug for a respiratory infection that is particularly serious for people with chronic obstructive pulmonary disease.
-
2 weeks ago | 
createsend.com | Brian Gormley
Good day. Knownwell,a Boston-based provider of primary-care and metabolic-health services to people who are overweight or obese, is expanding in the U.S. as it navigates insurance challenges in various geographic markets.
Knownwell, which says it offers comprehensive, non-stigmatizing care, raised seed financing in 2022 and the following year opened its first clinic in the Needham suburb of Boston.
-
2 weeks ago | 
createsend.com | Brian Gormley
Good day. Biotechnology company Glycomine is trying to create the first approved therapy for a rare and potentially life-threatening genetic disease that causes symptoms such as ataxia, or loss of muscle coordination.
The San Carlos, Calif.-based company recently raised a $115 million Series C financing to take aim at the disease, known as PMM2-CDG.
-
3 weeks ago | 
createsend.com | Brian Gormley
Good day. The global trade war has jolted financing markets, forcing many startups to consider alternatives to venture capital and initial public offerings. Haim Zaltzman, global vice chair of the emerging companies and growth practice of law firm Latham & Watkins, has been advising entrepreneurs as they navigate the turbulence. We spoke about financing alternatives with Zaltzman, whose practice includes work with biotech and medical-device startups, and venture and debt investors in these sectors.
-
1 month ago | 
createsend.com | Brian Gormley
Good day. Digital-health startups can capitalize on uncertain times to make big leaps if they are willing to take risks on creative business models and strategies, according to an analysis by Rock Health.
The conventional playbook of raising rounds of venture capital until a company is acquired or goes public isn’t always the best approach for startups innovating in areas such as healthcare artificial intelligence or virtual care.
-
1 month ago | 
wsj.com | Brian Gormley
Turbulence in the capital markets is driving biotechnology startups and venture capitalists to consider strategies such as forming closer ties to large pharmaceutical companies. With optimism budding early this year, biotechs raised $6.3 billion in venture capital in the first quarter, a faster pace than in 2024, when these companies collected $23.6 billion for the full year, according to investment bank William Blair. Biotechs raised $5.4 billion in the first quarter of 2024.
-
1 month ago | 
wsj.com | Brian Gormley
New investors Menlo Ventures, SignalFire back startup as insurance coverage for patient advocacy expandsApril 3, 2025 6:00 am ET|WSJ ProSolace has raised $60 million in new venture financing, double what it originally sought, as insurance coverage for the healthtech startup’s patient-advocacy services has expanded.
